Results 91 to 100 of about 60,957 (246)

Gut microbiome‐derived metabolites show promise in cancer research and therapy

Interdisciplinary Medicine, EarlyView.
The metabolites produced by the gut microbiome, which are subject to regulation by multiple factors, play a pivotal role in the progression of various types of cancer. These metabolites not only function as potential biomarkers for the early detection and monitoring of tumor development, but also actively participate in cancer therapeutic processes ...
Kangjie Yang, Yifan Wang, Daolin Tang, Peilong Li, Lutao Du   +4 more
wiley   +1 more source

Type II mode of JAK2 inhibition and destabilization are potential therapeutic approaches against the ruxolitinib resistance driven myeloproliferative neoplasms

Frontiers in Oncology
BackgroundRuxolitinib has been approved by the US FDA for the treatment of myeloproliferative neoplasms such as polycythemia vera and primary myelofibrosis.
Sivahari P. Gorantla, Sivahari P. Gorantla, Gerin Prince, Jasmin Osius, Dhurvas Chandrasekaran Dinesh, Vijay Boddu, Justus Duyster, Nikolas von Bubnoff   +7 more
doaj   +1 more source

Efficacy of Ritlecitinib for Vitiligo Treatment Stratified by Baseline Demographic and Clinical Characteristics: Post Hoc Analysis of a Phase 2b Study

JEADV Clinical Practice, EarlyView.
This post hoc analysis examined the efficacy of ritlecitinib in subgroups of patients with vitiligo, defined by demographic and clinical characteristics. Patients completed the dose‐ranging and extension periods of the phase 2b study (NCT03715829) of ritlecitinib.
A. G. Pandya, I. Hamzavi, P. Ghosh, K. Ezzedine, J. E. Harris, R. Adiri, S. Chen, E. Peeva, Y. Yamaguchi   +8 more
wiley   +1 more source

Macrophage JAK2 deficiency protects against high-fat diet-induced inflammation

Scientific Reports, 2017
During obesity, macrophages can infiltrate metabolic tissues, and contribute to chronic low-grade inflammation, and mediate insulin resistance and diabetes.
Harsh R. Desai, Tharini Sivasubramaniyam, Xavier S. Revelo, Stephanie A. Schroer, Cynthia T. Luk, Prashanth R. Rikkala, Adam H. Metherel, David W. Dodington, Yoo Jin Park, Min Jeong Kim, Joshua A. Rapps, Rickvinder Besla, Clinton S. Robbins, Kay-Uwe Wagner, Richard P. Bazinet, Daniel A. Winer, Minna Woo   +16 more
doaj   +1 more source

Systemic Absorption and Pharmacokinetics of Five Novel Topical Dermatologic Agents: A Review

JEADV Clinical Practice, EarlyView.
ABSTRACT In recent years, innovative topical medications with novel mechanisms of action have emerged to treat common dermatologic conditions such as acne, atopic dermatitis, vitiligo, and actinic keratoses. These molecularly targeted therapies offer improved safety and tolerability compared to traditional options like corticosteroids.
Mary Dyson, Kara Hurley, Hannah Chaudhury, Lara Shehadeh, Cameron West   +4 more
wiley   +1 more source

New Biologic and Small Molecule Therapies for Hidradenitis Suppurativa

JEADV Clinical Practice, EarlyView.
ABSTRACT Hidradenitis suppurativa (HS) is an inflammatory skin disease that has historically been underdiagnosed and, until recently, under‐researched. Furthermore, the pathophysiology of HS is complex, and not fully understood. Just three biologic medications—adalimumab (anti‐TNF‐α), secukinumab (anti‐IL17A) and bimekizumab (anti‐IL17A/F) are licensed
Emily Pender, Rosalind Hughes, Brian Kirby   +2 more
wiley   +1 more source

Respiratory Syncytial Virus (RSV): A Comprehensive Overview From Basic Biology to Clinical Prevention and Control

Medicinal Research Reviews, EarlyView.
ABSTRACT Respiratory syncytial virus (RSV) is a common virus that causes respiratory infections, posing a serious threat, particularly to infants, the elderly, and individuals with compromised immune systems. As the leading cause of lower respiratory tract infections (LRTIs) in infants, RSV is responsible for millions of cases worldwide each year.
Jie Shi, Xiya Huang, Chunjun Ye, Yishan Lu, Yanyan Liu, Yuquan Wei, Xiawei Wei   +6 more
wiley   +1 more source

The Drug Safety Framework of Avacopan: A Pharmacovigilance Study

Medicine Advances, EarlyView.
We identified 11 previously unreported potential adverse events associated with avacopan. No high‐priority clinical events were observed; however, special attention should be paid to the potential possibility of avacopan‐induced vanishing bile duct syndrome (Logos and icons displayed in the sections “Safety Framework” and “Data Sources and ...
Tianqi Chang, Xiaohong Xin, Xian Shao, Dikang Pan, Jingyu Wang   +4 more
wiley   +1 more source

Investigation of the Mechanism of Cinnamaldehyde in Irritable Bowel Syndrome Based via Network Pharmacology, Molecular Docking, and Animal Experiments

Pediatric Discovery, EarlyView.
Through network pharmacology and molecular docking, it has been discovered that CA can target MAOB, among other proteins, to exert a therapeutic effect in IBS. In vivo, CA lowered visceral hypersensitivity, anxiety and depression‐like behaviors, and fecal water content, highlighting its therapeutic potential for IBS via anti‐inflammatory pathways ...
Qingyang Yu, Boqing Xu, Chunfang Dai, Yayan Pang, Zhifang Dong   +4 more
wiley   +1 more source

Uric Acid in Metabolic Dysfunction‐Associated Steatotic Liver Disease

Portal Hypertension &Cirrhosis, EarlyView.
MASLD is the most prevalent chronic liver disease worldwide, yet effective pharmacological treatments remain limited. Hyperuricemia is now recognized as a key driver of hepatic steatosis, inflammation, and fibrosis, with elevated serum uric acid levels independently predicting hepatocellular carcinoma and liver‐related mortality.
Rong Wang, Zhenyu Liu, Jun Lin, Weijing Zhang, Xianzhi Liu, Tong Zhang   +5 more
wiley   +1 more source